Alzheimer Industry Analysis

Obtain global insight into Alzheimer's disease markets, information such as Neurodegenerative drug therapies and insight.

Change currency
Alzheimer's disease -Technologies, Markets and Companies (JAI00023)
Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable...		May 2012 £2,210
Alzheimer's Disease: Lifecycle Pharma Forecast, 2012-2035 – Europe (SLT00002)
SlideScript's Lifecycle Pharma Forecast reports deliver essential therapy area benchmarking data and quantitative market estimates projected across multiple regions and individual countries. Data-rich tables enable rapid understanding of market values,...		Feb 2012 £3,400
Alzheimer's Disease: Lifecycle Pharma Forecast, 2012-2035 - BRIC: Brazil, Russia, India, China (SLT00004)
SlideScript's Lifecycle Pharma Forecast reports deliver essential therapy area benchmarking data and quantitative market estimates projected across multiple regions and individual countries. Data-rich tables enable rapid understanding of market values,...		Feb 2012 £3,400
Alzheimer's Disease: Lifecycle Pharma Forecast, 2012-2035 - North America and Asia-Pacific (SLT00003)
SlideScript's Lifecycle Pharma Forecast reports deliver essential therapy area benchmarking data and quantitative market estimates projected across multiple regions and individual countries. Data-rich tables enable rapid understanding of market values,...		Feb 2012 £3,400
Alzheimer’s Disease Patients & Market Worldwide (RNR00023)
Future Scenario (2010 – 2015) & Drugs AnalysisAlzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s...		Jun 2011 £600
Alzheimer's Disease (BPR00012)
Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011This report presents a comprehensive review of autoantibodies, and pipeline vaccines and therapeutic antibodies, in Alzheimer’s disease (AD). Currently, drug treatments for AD are dominated by cholinesterase inhibitors and an...		Mar 2011 £1,500
Alzheimer's Disease Biomarkers in Cerebrospinal Fluid and Blood (BPR00005)
2011This report provides an overview of biomarkers associated with Alzheimer’s disease (AD) found in cerebrospinal fluid and blood, that have potential in differential diagnosis, in following treatment, in clinical trials...		Feb 2011 £650
Alzheimer's Disease (GDA00773)
Pipeline Assessment and Market Forecasts to 2017GlobalData, the industry analysis specialist, has released its new report, ""Alzheimer's Disease - Pipeline Assessment and Market Forecasts to 2017"". The report is an essential source of information and...		Nov 2010 £1,260
Tau and Amyloid Beta Targeted Therapy of Alzheimer's Disease (LME00122)
Competitor AnalysisThe present Competitive Intelligence Report about Tau and Amyloid Beta Targeted Therapy of Alzheimer's Disease provides a competitor evaluation in the field of therapeutic vaccines, antibodies and small molecules targeting...		Aug 2010 £580
U.S. Alzheimer's Disease Medication Market (FRS02026)
This research service provides an indepth analysis of factors affecting the growth of the U.S. Alzheimer's disease medication market over the period 2006-2016. Following an introduction to the market, which...		Aug 2010 £3,785
Alzheimer’s Disease Immunotherapy Pipeline (BPR00015)
Vaccines, Therapeutic Antibodies and Emerging StrategiesCurrent drug treatments for Alzheimer’s Disease (AD) are dominated by two drug classes: the cholinesterase inhibitors (e.g. Aricept®) and, more recently, an NMDA receptor antagonist (e.g. Ebixa®). While these drugs...		Jul 2010 £1,500
Alzheimer's Disease: Competing Treatments and Market Entry Considerations (BPR00018)
Presents the findings of a clinical survey of current treatment practices for Alzheimer’s Disease (AD). This was carried out following the participation of more than 220 physicians, practicing predominantly in...		Jun 2010 £1,500
Alzheimer's Disease Therapeutics and Diagnostics (BCC00340)
Global MarketsIntroduction Study Goals and Objectives BCC's Goal in Conducting This Study Was to Determine The Current Status of The Alzheimer's Disease Treatments and Diagnostics and Assess The Growth Potential of This...		Jan 2010 £3,060
Chinese Markets for Alzheimer Disease Drugs (AMI00389)
China's demand for Alzheimer Disease Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow....		Apr 2009 £2,525
Global Alzheimer Drugs Market (KOA04350)
An AnalysisThe Alzheimer's disease (AD) diagnosis and therapy market is expanding with increasing number of cases worldwide. The current scenario shows bright outlook for diagnosis market. As early diagnosis of AD...		Mar 2009 £435
China Senile Dementia Drug Market Report (DHC00010)
The Chinese Dementia Drug UtilizationBy conservative estimates, there are about 6 million Chinese senile dementia (SD) patients (including vascular dementia, Alzheimer's disease and other types of dementia patients). It is estimated that there will...		Mar 2009 £5,050
Alzheimers Disease Antibodies (LME00023)
Competitor AnalysisProduct description The Competitive Intelligence Report Alzheimer's Disease Antibodies as of July 2008 provides a competitor analysis in the development pipeline of novel antibodies for passive immunotherapy of Alzheimers disease including...		Jul 2008 £83
Diagnostic and Therapeutic Trends in Alzheimer's Disease (Technical Insights) (FRS00587)
This research service analyses the latest diagnostic and therapeutic developments that have occurred in the Alzheimer's disease sector, both from a technology and industry perspective.		Jun 2008 £4,100
Alzheimer's and Parkinson's Disease (GIA00077)
This report analyzes the worldwide markets for Alzheimer's and Parkinson's Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer's Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and Anti-Parkinson's...		May 2008 £2,490